Print this page
-
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma.
Protocol: 112303Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Bones and Joints -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.
Protocol: 112305Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Hodgkin's Lymphoma -
A bilingual virtually-based intervention (PEDALL) for the prevention of weight gain in childhood ALL patients considering key genetic and sociodemographic risk factors
Protocol: 112307Principal Investigator:
- Peter D. Cole
Applicable Disease Sites: Any Site -
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors.
Protocol: 112401-01APrincipal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Protocol: 112401-01CPrincipal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
A Phase 2/3 Randomized, Multicenter Study of Osivelotor
Administered Orally to Participants with Sickle Cell Disease and an
Open-Label Pharmacokinetics Study in Pediatric Participants with
Sickle Cell Disease
Protocol: 112403Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: -
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma.
Protocol: 112404Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
ACNS2321: A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas
Protocol: 112409Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
An open-label, single-arm, multicenter, phase 3 study to assess pharmacokinetics, safety and tolerability of iptacopan in pediatric PNH patients 2 to <18 years of age
Protocol: 112501Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: -
Collection of Pediatric and Adult Research Specimens for CNS Malignancies.
Protocol: 112503Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT).
Protocol: 112504Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Any Site -
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB).
Protocol: 112505Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lung -
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis.
Protocol: 112506Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Other Hematopoietic -
A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly Diagnosed Acute Lymphoblastic Leukemia with Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax.
Protocol: 112507Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Lymphoid Leukemia -
A Phase 3 Study of Sodium Thiosulfate for the Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy for Children with Medulloblastoma with Low-Risk Features.
Protocol: 112509Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System